Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 22:13:1211935.
doi: 10.3389/fonc.2023.1211935. eCollection 2023.

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

Angelo Maiolino  1   2 , Elaine Sobral Da Costa  1 , Alberto Orfao  3
Affiliations
Editorial

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

Angelo Maiolino et al. Front Oncol. .
No abstract available

Keywords: disease monitoring; flow cytometry; minimal residual disease; multiple myeloma; prognostic factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Minimal residual disease (MRD) assessment in multiple myeloma patients

References

    1. Puertas B, González-Calle V, Sobejano-Fuertes E, Escalante F, Queizán JA, Bárez A, et al. . Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers (Basel) (2023) 15(5):1558. doi: 10.3390/cancers15051558 - DOI - PMC - PubMed
    1. Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. . Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol (2017) 3:28–35. doi: 10.1001/jamaoncol.2016.3160 - DOI - PMC - PubMed
    1. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. . International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol (2016) 17:e328–46. doi: 10.1016/S1470-2045(16)30206-6 - DOI - PubMed
    1. Lahuerta J-J, Paiva B, Vidriales M-B, Cordón L, Cedena M-T, Puig N, et al. . Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol (2017) 35:2900–10. doi: 10.1200/JCO.2016.69.2517 - DOI - PMC - PubMed
    1. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. . Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia (2017) 31:2094–103. doi: 10.1038/leu.2017.29 - DOI - PMC - PubMed

Publication types

LinkOut - more resources